Navigating the Build vs. Buy Debate for Member Engagement Solutions

The evolving landscape of healthcare demands that health plans continuously refine their engagement strategies, making this decision more critical than ever. Plan leaders must consider key factors, including cost, speed, scalability, and effectiveness, to guide them toward the most impactful approach. The post Navigating the Build vs. Buy Debate for Member Engagement Solutions appeared first…

Read More

Denali’s Data in Rare Enzyme Deficiency Keep It on Pace to Seek Speedy FDA Approval

Currently available therapies for Hunter syndrome don’t cross the blood-brain barrier to address cognitive symptoms of the inherited enzyme deficiency. Denali Therapeutics’ technology gets its drug across the protective membrane, and the biotech plans to seek accelerated FDA approval in this rare disease. The post Denali’s Data in Rare Enzyme Deficiency Keep It on Pace…

Read More

“Precision Med Has Evolved as Badly As I Expected” And OtherTakeaways From Former FDA Commissioner At PMWC

Robert Califf addressed a range of issues, including AI, lack of nutrition resources at the FDA and how he evaluates the progress of precision medicine at the Precision Medicine World Conference in Silicon Valley. The post “Precision Med Has Evolved as Badly As I Expected” And OtherTakeaways From Former FDA Commissioner At PMWC appeared first…

Read More